|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,936.50 GBX | +1.10% |
|
-0.18% | +6.14% |
| Aug. 06 | LifeMine Therapeutics, Inc. announced that it has received $188 million in funding from a group of investors | CI |
| Aug. 05 | US FDA approves first mRNA flu shot from Moderna | RE |
| Market Cap | 77.6B 104B 90.59B 84.83B 146B 9,944B 148B 992B 389B 4,968B 392B 383B 16,537B | P/E 2026 * |
13.4x | P/E 2027 * | 11.7x |
|---|---|---|---|---|---|
| Enterprise Value | 95.59B 129B 112B 104B 180B 12,250B 183B 1,222B 480B 6,120B 483B 472B 20,371B | EV / Sales 2026 * |
2.82x | EV / Sales 2027 * | 2.6x |
| Free-Float |
92.75% | Yield 2026 * |
3.59% | Yield 2027 * | 3.78% |
Last Transcript: GSK plc
| Aug. 04 | Merck's Weekly HIV Treatment Pipeline 'Interesting,' UBS Says | MT |
| Aug. 04 | GSK : JP Morgan gives a Sell rating | ZD |
| Aug. 03 | RBC cuts JD Sports; Jefferies cuts Severn Trent | AN |
| Aug. 03 | GSK : Buy rating from Bernstein | ZD |
| Jul. 30 | GSK : Deutsche Bank gives a Neutral rating | ZD |
| 1 day | +1.10% | ||
| 1 week | -0.18% | ||
| Current month | +0.26% | ||
| 1 month | -2.34% | ||
| 3 months | +3.28% | ||
| 6 months | -11.90% | ||
| Current year | +6.14% |
| 1 week | 1,890 |  | 1,964.5 |
| 1 month | 1,850.5 | | 2,096 |
| Current year | 1,690 | | 2,282 |
| 1 year | 1,288.6 | | 2,282 |
| 3 years | 1,242.5 | | 2,282 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 2025-12-31 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 2023-04-30 |
| Chief Tech/Sci/R&D Officer | - | 2021-11-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Luke Miels
BRD | Director/Board Member | - | 2026-05-05 |
Hal Barron
BRD | Director/Board Member | 64 | 2017-12-31 |
Jonathan Symonds
CHM | Chairman | 68 | 2019-08-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 7/29/26 | Sell | Executive/Senior Manager | -38,000 | 0.0009% | ||
| 7/22/26 | Buy | Executive/Senior Manager | 9 | 0.0000% | ||
| 7/14/26 | Buy | Chief Technology Officer | 660 | 0.0000% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.10% | -0.18% | +41.04% | +43.76% | 103B | |
| +1.89% | +3.20% | +59.70% | +165.18% | 1,043B | |
| -0.24% | +0.45% | +50.64% | +52.02% | 621B | |
| -0.95% | -5.26% | +24.23% | +65.08% | 435B | |
| 0.00% | +3.20% | +46.70% | +37.60% | 361B | |
| +0.58% | -1.26% | +35.52% | +40.54% | 293B | |
| -1.55% | -6.84% | +7.20% | +8.62% | 251B | |
| -0.73% | +4.44% | +42.22% | +66.41% | 220B | |
| -0.24% | -11.27% | +1.42% | -44.69% | 201B | |
| -0.68% | -0.32% | +18.66% | +66.32% | 164B | |
| Average | -0.36% | -2.41% | +32.73% | +50.08% | 369.25B | |
| Weighted average by Cap. | -0.50% | -1.38% | +40.68% | +76.25% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 33.95B 45.68B 39.64B 37.12B 64.1B 4,351B 64.94B 434B 170B 2,174B 172B 168B 7,236B | 35.63B 47.93B 41.6B 38.95B 67.26B 4,566B 68.14B 456B 179B 2,281B 180B 176B 7,593B |
| Net income | 5.78B 7.77B 6.74B 6.32B 10.91B 740B 11.05B 73.88B 29B 370B 29.18B 28.55B 1,231B | 6.6B 8.87B 7.7B 7.21B 12.45B 845B 12.61B 84.36B 33.11B 422B 33.32B 32.59B 1,406B |
| Net Debt | 17.99B 24.2B 21B 19.67B 33.97B 2,306B 34.41B 230B 90.3B 1,152B 90.88B 88.9B 3,834B | 15.09B 20.3B 17.62B 16.5B 28.49B 1,934B 28.86B 193B 75.74B 966B 76.23B 74.57B 3,216B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-08-06 | GBX 1,936.50 | +1.10% | 3,139,064 |
| 26-08-05 | GBX 1,915.50 | +0.05% | 8,739,818 |
| 26-08-04 | GBX 1,914.50 | +0.26% | 6,267,337 |
| 26-08-03 | GBX 1,909.50 | -1.14% | 5,577,529 |
| 26-07-31 | GBX 1,931.50 | -0.44% | 6,864,229 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
